<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36116127</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Diagnostic criteria in amyotrophic lateral sclerosis: Time for a change.</ArticleTitle><Pagination><StartPage>E34</StartPage><EndPage>E35</EndPage><MedlinePgn>E34-E35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27723</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jewett</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-8268-5677</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khayambashi</LastName><ForeName>Shahin</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5972-5901</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frost</LastName><ForeName>Geoffrey S</ForeName><Initials>GS</Initials><Identifier Source="ORCID">0000-0002-6340-2299</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beland</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-9574-1412</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Angela</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9483-975X</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodgkinson</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5908-2694</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korngut</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-1594-5923</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhibber</LastName><ForeName>Sameer</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Muscle Nerve. 2022 Oct;66(4):377-379</RefSource><PMID Version="1">35822531</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">El Escorial criteria</Keyword><Keyword MajorTopicYN="N">Gold Coast criteria</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>18</Day><Hour>16</Hour><Minute>59</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36116127</ArticleId><ArticleId IdType="doi">10.1002/mus.27723</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Shefner JM. Changing amyotrophic lateral sclerosis diagnostic criteria: will it impact clinical trials? Muscle Nerve. 2022;66(4):377-379. doi:10.1002/mus.27676</Citation></Reference><Reference><Citation>Jewett G, Khayambashi S, Frost GS, et al. Gold Coast criteria expand clinical trial eligibility in amyotrophic lateral sclerosis. Muscle Nerve. 2022;66(4):397-403. doi:10.1002/mus.27660</Citation></Reference><Reference><Citation>Andrews JA, Jackson CE, Heiman-Patterson TD, Bettica P, Brooks BR, Pioro EP. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:1-10. doi:10.1080/21678421.2020.1771734</Citation></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/Riluzole study group II. Lancet. 1996;347:1425-1431. doi:10.1016/s0140-6736(96)91680-3</Citation></Reference><Reference><Citation>van Eijk RPA, Westeneng H-J, Nikolakopoulos S, et al. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. 2019;92(5):e451-e460. doi:10.1212/WNL.0000000000006855</Citation></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919-930. doi:10.1056/NEJMoa1916945</Citation></Reference><Reference><Citation>CADTH. Reimbursement Recommendation: Sodium Phenylbutyrate and Ursodoxicoltaurine (Albrioza). https://www.cadth.ca/sites/default/files/DRR/2022/SR0711REC-Albrioza.pdf. Accessed 19 August, 2022.</Citation></Reference><Reference><Citation>Pinto S, de Carvalho M. Correlation between forced vital capacity and slow vital capacity for the assessment of respiratory involvement in amyotrophic lateral sclerosis: a prospective study. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:86-91. doi:10.1080/21678421.2016.1249486</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>